SAREPTA THERAPEUTICS, INC. Research and Development in Process
SAREPTA THERAPEUTICS, INC. (SRPT) reported Research and Development in Process of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2022-03-01
- SAREPTA THERAPEUTICS, INC. research and development in process for the quarter ending 2019-12-31 was $0.00.
- SAREPTA THERAPEUTICS, INC. research and development in process for the quarter ending 2019-09-30 was $0.00.
- SAREPTA THERAPEUTICS, INC. research and development in process for the quarter ending 2019-06-30 was $173.24M.
- SAREPTA THERAPEUTICS, INC. research and development in process for the quarter ending 2012-12-31 was $0.00.
- SAREPTA THERAPEUTICS, INC. research and development in process for fiscal 2021 was $0.00.
- SAREPTA THERAPEUTICS, INC. research and development in process for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- SAREPTA THERAPEUTICS, INC. research and development in process for fiscal 2019 was $173.24M.
- SAREPTA THERAPEUTICS, INC. research and development in process for fiscal 2012 was $0.00.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month | Research and Development in Process 371 month | Research and Development in Process 374 month | Research and Development in Process 377 month | Research and Development in Process 380 month | Research and Development in Process 383 month | Research and Development in Process 386 month | Research and Development in Process 389 month | Research and Development in Process 392 month | Research and Development in Process 395 month | Research and Development in Process 398 month | Research and Development in Process 401 month | Research and Development in Process 404 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-01 | |||||||||||||||
| 2020-12-31 | $0.00 10-K · filed 2022-03-01 | |||||||||||||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $0.00 derived: sum of 2 quarters · filed 2022-03-01 | $173.24M derived: sum of 3 quarters · filed 2022-03-01 | $173.24M 10-K · filed 2022-03-01 | ||||||||||||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $173.24M derived: sum of 2 quarters · filed 2021-03-01 | $173.24M 10-Q · filed 2020-11-05 | |||||||||||||
| 2019-06-30 | $173.24M 10-K · filed 2021-03-01 | $173.24M 10-Q · filed 2020-08-05 | ||||||||||||||
| 2014-03-31 | $29.46M 10-Q · filed 2014-05-08 | |||||||||||||||
| 2013-12-31 | $29.46M 10-K · filed 2014-03-03 | |||||||||||||||
| 2013-09-30 | $29.46M 10-Q · filed 2013-11-12 | |||||||||||||||
| 2013-06-30 | $29.46M 10-Q · filed 2013-08-08 | |||||||||||||||
| 2013-03-31 | $29.46M 10-Q · filed 2013-05-09 | |||||||||||||||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $0.00 derived: sum of 2 quarters · filed 2013-03-15 | $0.00 derived: sum of 3 quarters · filed 2013-03-15 | $0.00 10-K · filed 2013-03-15 | $29.46M 10-K · filed 2013-03-15 | |||||||||||
| 2012-09-30 | $0.00 10-Q · filed 2012-11-07 | $0.00 derived: sum of 2 quarters · filed 2012-11-07 | $0.00 10-Q · filed 2012-11-07 | $0.00 derived: sum of 4 quarters · filed 2013-03-15 | $29.46M 10-Q · filed 2012-11-07 | |||||||||||
| 2012-06-30 | $0.00 10-Q · filed 2012-08-07 | $0.00 10-Q · filed 2012-08-07 | $0.00 derived: sum of 3 quarters · filed 2013-03-15 | $0.00 derived: sum of 4 quarters · filed 2013-03-15 | $29.46M 10-Q · filed 2012-08-07 | |||||||||||
| 2012-03-31 | $0.00 10-Q · filed 2012-05-10 | $0.00 derived: sum of 2 quarters · filed 2013-03-15 | $0.00 derived: sum of 3 quarters · filed 2013-03-15 | $0.00 derived: sum of 4 quarters · filed 2013-03-15 | $29.46M 10-Q · filed 2012-05-10 | |||||||||||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $0.00 derived: sum of 2 quarters · filed 2013-03-15 | $0.00 derived: sum of 3 quarters · filed 2013-03-15 | $0.00 10-K · filed 2013-03-15 | $29.46M 10-K · filed 2012-03-13 | |||||||||||
| 2011-09-30 | $0.00 10-Q · filed 2012-11-07 | $0.00 derived: sum of 2 quarters · filed 2012-11-07 | $0.00 10-Q · filed 2012-11-07 | $29.46M 10-Q · filed 2011-11-08 | ||||||||||||
| 2011-06-30 | $0.00 10-Q · filed 2012-08-07 | $0.00 10-Q · filed 2012-08-07 | $29.46M 10-Q · filed 2011-08-08 | |||||||||||||
| 2011-03-31 | $0.00 10-Q · filed 2012-05-10 | |||||||||||||||
| 2010-12-31 | $0.00 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |